Kang Catherine E, Poon Peter C, Tator Charles H, Shoichet Molly S
Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada.
Tissue Eng Part A. 2009 Mar;15(3):595-604. doi: 10.1089/ten.tea.2007.0349.
After spinal cord injury (SCI), a complex cascade of events leads to tissue degeneration and a penumbra of cell death. Neuroprotective molecules to limit tissue loss are promising; however, intravenous delivery is limited by the blood-spinal cord barrier and short systemic half-life. Current local delivery strategies are flawed: bolus injection results in drug dispersion throughout the intrathecal (IT) space, and catheters/pumps are invasive and open to infection. Our laboratory previously developed a hydrogel of hyaluronan (HA) and methylcellulose (MC) (HAMC) that, when injected into the IT space, was safe and, remarkably, had some therapeutic benefit on its own. In order to test this new paradigm of local and sustained delivery, relative to conventional delivery strategies, we tested, for the first time, the in vivo efficacy of HAMC as an IT drug delivery system by delivering a known neuroprotective molecule, erythropoietin (EPO). In vitro studies showed that EPO was released from HAMC within 16 h, with 80% bioactivity maintained. When the material alone was injected in vivo, individual fluorescent labels on HA and MC showed that HA dissolved from the gel within 24 h, whereas the hydrophobically associated MC persisted in the IT space for 4-7 days. Using a clip compression injury model of moderate severity, HAMC with EPO was injected in the IT space and, in order to better understand the potential of this delivery system, compared to the therapeutic effect of both common delivery strategies-IT EPO and intraperitoneal EPO-and a control of IT HAMC alone. IT HAMC delivery of EPO resulted in both reduced cavitation after SCI and a greater number of neurons relative to the other delivery strategies. These data suggest that the localized and sustained release of EPO at the tissue site by HAMC delivery enhances neuroprotection. This new system of IT delivery holds great promise for the safe, efficacious, and local delivery of therapeutic molecules directly to the spinal cord.
脊髓损伤(SCI)后,一系列复杂的事件会导致组织退化和细胞死亡半暗带。限制组织损失的神经保护分子很有前景;然而,静脉给药受到血脊髓屏障和较短的全身半衰期的限制。当前的局部给药策略存在缺陷:推注会导致药物在鞘内(IT)空间扩散,而导管/泵具有侵入性且易感染。我们实验室之前开发了一种透明质酸(HA)和甲基纤维素(MC)的水凝胶(HAMC),将其注入IT空间时是安全的,而且令人惊讶的是,它自身就具有一定的治疗益处。为了测试这种局部和持续给药的新范式相对于传统给药策略的效果,我们首次通过递送一种已知的神经保护分子促红细胞生成素(EPO)来测试HAMC作为IT药物递送系统的体内疗效。体外研究表明,EPO在16小时内从HAMC中释放出来,保持了80%的生物活性。当单独将该材料注入体内时,HA和MC上的单个荧光标记显示,HA在24小时内从凝胶中溶解,而疏水结合的MC在IT空间中持续存在4至7天。使用中度严重程度的夹压损伤模型,将含有EPO的HAMC注入IT空间,为了更好地了解这种递送系统的潜力,将其与两种常见给药策略(IT EPO和腹腔内EPO)的治疗效果以及单独的IT HAMC对照进行比较。与其他递送策略相比,通过IT HAMC递送EPO可减少SCI后的空洞形成,并增加神经元数量。这些数据表明,通过HAMC递送在组织部位局部和持续释放EPO可增强神经保护作用。这种新的IT递送系统对于将治疗分子安全、有效且局部地直接递送至脊髓具有巨大的潜力。